Analytical Data
-
Gene name
BAGE2
- Application
-
Alternative Names
Cancer/testis antigen 2.2
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q86Y30
-
Expression Region
18-109aa
-
Molecular Weight
17.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The BAGE2 protein, part of the BAGE (B melanoma antigen gene) family, has garnered significant interest in cancer research due to its potential role in tumor immunology and as a target for cancer immunotherapy. Identified as an antigen expressed in various tumors but absent in most normal tissues, BAGE2 presents a promising avenue for the development of targeted therapies aimed at harnessing the body’s immune response against malignant cells. Research indicates that BAGE2 is associated with cancer progression, particularly in melanoma and other malignancies, making it a candidate for therapeutic vaccines and personalized medicine strategies. Additionally, studies have shown its involvement in immune evasion mechanisms, contributing to the challenges faced in effective cancer treatment. Understanding the expression patterns, immunogenicity, and functional roles of BAGE2 is crucial for both diagnostic and therapeutic advancements in oncology, emphasizing the need for continued investigation into its molecular characteristics and potential applications in cancer immunotherapy.
